Clinical Trials Browser

Completed × INDUSTRY × etirinotecan pegol × Clear all

NCT02915744 2023-04-14

ATTAIN

Phase 3 Completed

178 enrolled 37 charts

Breast Neoplasms, Carcinoma, Neoplasm Metastasis

NCT00598975 2021-07-12

NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b)

Phase 2 Completed

18 enrolled 13 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT00856375 2021-07-12

NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer

Phase 2 Completed

83 enrolled 13 charts

Gastrointestinal

Colorectal Neoplasms

NCT01457118 2021-07-12

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Phase 2 Completed

27 enrolled 18 charts

Other solid neoplasm

Malignant Solid Tumor

NCT01492101 2021-06-01

BEACON

Phase 3 Completed

852 enrolled 21 charts

Breast Neoplasms

NCT00802945 2018-07-09

Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer

Phase 2 Completed

70 enrolled 15 charts

Breast Neoplasms, Neoplasms

NCT01976143 2016-12-22

A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety

Phase 1 Completed

Other solid neoplasm

Advanced Cancer